Register Login

XILIO THERAPEUTICS, INC. (XLO)

SymbolXLO
NameXILIO THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address828 WINTER STREET,SUITE 300, WALTHAM, Massachusetts, 02451, United States
Telephone+1 857 - 524-2466
Fax—
Email—
Websitehttps://www.xiliotx.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001840233
Description

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.

Additional info from NASDAQ:
Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.

2026-08-14 13:02

New Form SCHEDULE 13G/A - Xilio Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-096755 <b>Size:</b> 17 KB

Read more
2026-08-12 11:35

(10% Negative) XILIO THERAPEUTICS, INC. (XLO) Reports Q3 2026 Financial Results

Read more
2026-08-12 11:30

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

Read more
2026-08-12 08:46

New Form S-8 - Xilio Therapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001193125-26-345762 <b>Size:</b> 695 KB

Read more
2026-07-06 20:30

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-06-29 11:30

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

Read more
2026-06-12 20:07

Bello Akintunde Olatokumbo 🟢 acquired 5.0K shares (1 derivative) of Xilio Therapeutics, Inc. (XLO) at $7.99 Transaction Date: Jun 11, 2026 | Filing ID: 269399

Read more
2026-06-12 20:07

ROSS ROBERT W. 🟢 acquired 5.0K shares (1 derivative) of Xilio Therapeutics, Inc. (XLO) at $7.99 Transaction Date: Jun 11, 2026 | Filing ID: 269397

Read more
2026-06-12 20:07

Bonstein Sara 🟢 acquired 5.0K shares (1 derivative) of Xilio Therapeutics, Inc. (XLO) at $7.99 Transaction Date: Jun 11, 2026 | Filing ID: 269396

Read more
2026-06-12 20:07

Brennan Aoife 🟢 acquired 5.0K shares (1 derivative) of Xilio Therapeutics, Inc. (XLO) at $7.99 Transaction Date: Jun 11, 2026 | Filing ID: 269395

Read more